8:00 am Coffee Room Opens
8:50 am Chair’s Opening Remarks
Progress in Mutation-Driven NSCLC Drug Development in Earlier Lines of Therapy
9:00 am Breakfast Panel: Bridging the TKI vs. Immunotherapy Conversations in NSCLC
Synopsis
- Discussing stage of cancer, combinations, and order of treatment rationale for the well-validated
immunotherapies and TKIs in early lines - Exploring shifts of focus between the immune system of the patient (immunotherapies) and the
biology of the tumor (tyrosine kinase inhibitors) - How can we combine insights from both immune system markers and tumor markers, to be used as markers that
are predictive of patient response? - What are the rational targeted combinations for current TKIs?
9:30 am The RAF/MEK Clamp VS-6766 for Treatment of KRAS & BRAF Mutant NSCLC
Synopsis
- Exploring anti-tumor activity across multiple MAPK pathway alterations
- Ongoing VS-6766 combinations with FAK, KRAS G12C or mTOR inhibitors
- Revealing new combinations with EGFR inhibitors
10:00 am The Bispecific Antibody MCLA-129 Impairs EGFR Inhibitor Resistant NSCLC Tumor Growth by Targeting EGFR & c-MET
Synopsis
- Exploring the upregulation of c-MET signaling has been associated with
resistance to EGFR inhibition - Delving into MCLA-129: a bispecific antibody that blocks the signaling of EGFR as
well as c-MET, to inhibit tumor growth and survival - Understand how MCLA-129 utilizes ADCC-enhancement technology, which
increases its cell-killing potential by immune cells
10:30 am Morning Refreshments
11:00 am Inhibition of the WNT/beta catenin Pathway in NSCLC
Synopsis
- Understand the WNT/beta catenin pathway’s importance as a target in NSCLC
- Explore the new therapeutics in development to inhibit this target
- Combination with EGFR inhibitors has potential to impact disease progression
Immune Checkpoint Inhibitors & Rational Combinations to Improve Outcomes in Earlier Lines of Therapy
12:00 pm A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC
Synopsis
- An MHC class II agonist (eftilagimod) used as an antigen presenting cell (APC) activator combined with an immune checkpoint inhibitor (ICI)
- Results in first (114 patients) and second (36 PD-X refractory patients) lines NSCLC
- A systemic APC activator injected s.c. plus an ICI: a potent combination for PDL-1
unselected patients
12:30 pm Exploring the Adjuvant vs. Neoadjuvant Debate
Synopsis
- Understanding Nivolumab with chemotherapy as neoadjuvant treatment
- Discussing the data for adjuvant vs. neoadjuvant based on disease stage, actionable mutation status and PD-L1 status
- Delving into the thoughts and future directions of this dynamic conversation
1:00 pm Lunch & Networking
Optimizing Trial Design, Patient Recruitment & Patient Voice to Improve Trials
2:00 pm Utility of Blood-Based Molecular Diagnostic Testing Across the Lung Cancer Continuum of Care
2:30 pm Overcoming Barriers to Clinical Trial Enrollment in NSCLC
Synopsis
- Discussing thoughts on improving trial design, tailored towards clinical investigation during the pandemic
- Exploring telemedicine
- Overcoming barriers to trial enrollment
- Delving into smart trial design, optimizing study design in the midst of pandemic
3:00 pm Physician Panel Discussion: Challenges & Practical Insights Into Optimizing Drug Sequencing & Patient Enrolment
Synopsis
- Discussing clinical trial design and patient inclusion/exclusion criteria when investigating drug sequencing
- Challenges in running the trials from a patient selection and management perspective (especially with all the different lines of therapy as inclusion/exclusion/ selection criteria, meaning that many are not enrolled as they have been on a PD1 drug for a short time – how can pharma modify its inclusion criteria?)
- Exploring pain points and tips on patient enrolment for NSCLC clinical trials
- Analyzing sequencing: do you test the targeted therapy in a small biomarker select population or do you give that patient their first shot and the PD1, or do you put them together?
- What should come first: Immunotherapy when the patient has the strongest immune system or the small target agent?
- What is the role of chemotherapy in the above? And combining PD-1 with the TKI?
- After Pembro-chemo and/or Pembro-monotherapy in the PDL1 population, what do you do next?
- What is the progress in understanding the meaningful early biomarkers before you get to the 2-year endpoint?
3:30 pm Afternoon Refreshments
4:00 pm Patient Advocacy Groups as Partners in Drug Development
Synopsis
- PAGs like LUNGevity Foundation support patients with cancer in multiple ways, including by funding transformative research on disease biology, detection, and treatment
- LUNGevity has a demonstrated history of engaging stakeholders in the drug development ecosystem to address pain points and working together towards implementable solutions
4:15 pm Centering the Patient in Our NSCLC Drug Development Journey
Synopsis
- Discussing working with and informing patients, working with advocacy groups and more
4:30 pm Chair’s Closing Remarks & End of Summit
